ReviewPharmaceutics2017
An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.
Review in Pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 421 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
421 citing papers in PubMed.
- Chitosan-Based Nose-to-Brain Drug Delivery for Management of Neurological Disorders: Intrinsic Neuroprotective Action and Carrier Capabilities.AAPS PharmSciTech · 2026Review
- Performance of TPP-Crosslinked Nano-chitosan for Simultaneous Nutrient Adsorption in Nutrient-Rich Wastewater.ACS omega · 2026Article
- Optimized Chitosan Nanoparticles for Enhanced Ciprofloxacin Delivery and Activity Against Resistant Bacteria.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Article
- Chitosan-based nano-encapsulation enhances the anti-diabetic efficacy of Eremina desertorum extract by ameliorating hyperglycemia, oxidative stress, and inflammation in diabetic rats.Journal of materials science. Materials in medicine · 2026Article
- Light-Triggered and Sustained Delivery of Dexamethasone Using Chitosan-Coated PLGA Nanoparticles for Posterior Eye Disease Treatment.ACS omega · 2026Article
- Chitosan in aesthetic practice: A clinical narrative review of skin, scar, and scalp applications.JPRAS open · 2026Review
- Activation of the Complement System: Morphological Differences in the Surface of PIBCA Nanoparticles Coated with Polysaccharides.ACS nanoscience Au · 2026Article
- Chitosan nanoparticles for mucosal and needle-free vaccination.NPJ vaccines · 2026Review
- Chitosan-confined selenium-silver nanohybrids enable redox-modulated mitochondrial apoptosis and survival improvement in experimental hepatocellular carcinoma.RSC advances · 2026Article
- Recent advances in the application of polymeric nanoparticles to the pulmonary delivery of mRNA.Nanomedicine (London, England) · 2026Review
- Nanochitosan-based adsorbents for sustainable treatment of palm oil mill effluent.RSC advances · 2026Review
- Formulation of Metformin-Loaded Chitosan Nanoparticles and In Vivo Evaluation of Its Hypoglycemic Effects.Molecules (Basel, Switzerland) · 2026Article
- Chitosan-Based Taurine Nanoparticles Alleviate Dexamethasone-Induced Pulmonary-Thyroid Axis Dysfunction via Redox-Inflammatory Signaling Modulation in Rats.International journal of molecular sciences · 2026Article
- Nanoparticle embedded dot matrix transdermal patches: a novel approach for targeted and controlled drug delivery in rheumatoid arthritis.Inflammopharmacology · 2026Review
- Topical Anti-Inflammatory Therapies in Veterinary Medicine: Advancing Animal Health Through a One Health Approach.Animals : an open access journal from MDPI · 2026Review
- Chitosan nanoparticle encapsulated pentoxifylline improves renal protection and reduces oxidative stress in amikacin induced nephrotoxicity.Discover nano · 2026Article
- Emerging Trends in Chitin-Based Hydrogels: From Fundamental Properties to Advanced Applications.Gels (Basel, Switzerland) · 2026Review
- Stimuli-Responsive Carriers for Delivery of Anticancer Bioactive Agents.Materials (Basel, Switzerland) · 2026Review
- The Role of Biofunctional Polymers in Polymer-Drug Conjugates: From Passive Carriers to Therapeutically Active Platforms.Pharmaceutics · 2026Review
361 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The focus of this review is to provide an overview of the chitosan based nanoparticles for various non-parenteral applications and also to put a spotlight on current research including sustained release and mucoadhesive chitosan dosage forms. Chitosan is a biodegradable, biocompatible polymer regarded as safe for human dietary use and approved for wound dressing applications. Chitosan has been used as a carrier in polymeric nanoparticles for drug delivery through various routes of administration. Chitosan has chemical functional groups that can be modified to achieve specific goals, making it a polymer with a tremendous range of potential applications. Nanoparticles (NP) prepared with chitosan and chitosan derivatives typically possess a positive surface charge and mucoadhesive properties such that can adhere to mucus membranes and release the drug payload in a sustained release manner. Chitosan-based NP have various applications in non-parenteral drug delivery for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections which will be exemplified in this review. Chitosan shows low toxicity both in vitro and some in vivo models. This review explores recent research on chitosan based NP for non-parenteral drug delivery, chitosan properties, modification, toxicity, pharmacokinetics and preclinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.